FindTrial
Sign In

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002275
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2009-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Weight Loss, Pneumonia, Pneumocystis carinii, Parenteral Nutrition, Liposyn, Acquired Immunodeficiency Syndrome

Brief summary

The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.

Interventions

DRUGFat Emulsion 2%
DRUGFat Emulsion 20%

Sponsors

Abbott
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Concurrent Medication: Allowed: * All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP). * Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry. Patients must have: * Diagnosis of AIDS. * Weight loss \> 10 percent of premorbid body weight. * First or second episode of acute Pneumocystis carinii pneumonia (PCP).

Exclusion criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Do Not Resuscitate (DNR) status. * Biliary stasis. Patients with the following are excluded: * Do Not Resuscitate (DNR) status. * Biliary stasis. Prior Medication: Excluded within 3 months of study entry: * Immunomodulators. * Antiviral new DT

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026